List view / Grid view
3 October 2013 | By Teva Pharmaceutical Industries Ltd
Teva believes unpredictable differences between a proposed generic product and COPAXONE® could lead to immunogenic effects in patients...
3 October 2013 | By Teva Pharmaceutical Industries Ltd
“To our knowledge, glatiramer acetate is the only treatment for multiple sclerosis that has been prospectively studied for nearly two decades..."
3 October 2013 | By Novartis
"Controlling relapses and preventing disability are key treatment goals for patients with MS..."
2 October 2013 | By AstraZeneca
AstraZeneca announced that the US Court of Appeals for the Federal Circuit (CAFC) lifted a temporary injunction against the US launch of Hanmi's 505(b)2 NDA esomeprazole strontium product...
2 October 2013 | By AstraZeneca
Hanmi’s launch would be at risk of owing AstraZeneca patent-infringement damages...
1 October 2013 | By biogen idec
Analyses reinforce efficacy of PLEGRIDY, further supporting a potential new treatment option for people with multiple sclerosis...
1 October 2013 | By AstraZeneca
The growth of the BioHub complements the work of the Alderley Park taskforce to capitalise and build on the existing local bioscience network and expertise...
1 October 2013 | By Amgen
"Amgen's acquisition of Onyx fits perfectly with our commitment to advancing medicines for cancer patients around the world..."
1 October 2013 | By Johnson & Johnson
“Everyone needs a complete eye exam because that’s how you are more likely to prevent blindness and eye disease..."
1 October 2013 | By Teva Pharmaceutical Industries Ltd
"This Phase III sub-study was pre-planned to explore the ability of laquinimod to act on mechanisms leading to irreversible brain tissue damage..."
1 October 2013 | By Roche
Leading scientists join together to discuss breakthrough research that addresses serious medical needs...
1 October 2013 | By Novartis
Data from head-to-head pivotal study showing secukinumab (AIN457) superiority to Enbrel®* (etanercept) in moderate-to-severe plaque psoriasis to be revealed...
1 October 2013 | By Merck
An abstract (# 2416) published today summarized preliminary findings from 38 patients with NSCLC treated with MK-3475...
1 October 2013 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) announced today that 16 abstracts have been accepted for presentation at The Liver Meeting® 2013...
30 September 2013 | By GlaxoSmithKline
GlaxoSmithKline (LSE:GSK) today announced it has reached agreement to sell its thrombosis brands, Arixtra® and Fraxiparine®, and the Notre-Dame de Bondeville (NDB)...
